Register for the Annual Sickle Cell Disease Therapeutics Conference (SCDTC Livestream)
GBT is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease
Our goal is to transform the treatment of SCD, an overlooked rare condition, and help address the urgent needs of the community. Our mission is driven by the historical lack of understanding and attention given to SCD. Although the fundamental cause of SCD has been understood for decades, therapeutic innovation and access to care has significantly lagged.
The FDA approved GBT’s medicine as the first treatement to target an underlying cause of SCD. We are developing additional investigational treatments that have the potential to better the lives of patients.
Our commitment to the SCD community
We have a deep and urgent desire to improve the care of SCD patients. Beyond developing medicines, we are working to shine a bright light on the disparities and inequalities faced by people living with SCD. To this end, in July 2019 we launched Sickle Cell Speaks, a national campaign focused on breaking down stigmas associated with SCD.